

Latest Update: Jun 24, 2022

Arthritis, rheumatoid

Category: Immune System|Musculoskeletal

Antibody Therapies: 112

Antibody Name 	Targets 	Organization 	Status 
Dekavil	Fibronectin	Pfizer Philogen	Phase 2
efavaleukin alfa	IL-2R beta	Amgen	Phase 2
Etanercept	TNF α	Amgen Pfizer	Approved
Etanercept biosimilar, 3Sbio	TNF α	3SBio	Approved
Etanercept biosimilar, Zhejiang Hisun	TNF α	Zhejiang Hisun	Approved
Etanercept biosimilar - Mycenax Biotech/TS H Biopharm	TNF α	Mycenax	Approved
FR-104	CD28	OSE Immunotherapeutics Janssen Biotech	Phase 2
FB704A	IL-6	Fountain Oneness Biotech	Phase 2
golimumab	TNF α	Centocor J&J	Approved
gerilimumab	IL-6	argenx Bluebird Bio Genor (Walvax Biotechnology)	Phase 2
GR1501	IL-17	Genrix Biopharma	Phase 2
HuL001	ENO1	HuniLife	Phase 1
infliximab	TNF α	J&J Merck (MSD) Mitsubishi Tanabe	Approved
infliximab biosimilar, Celltrion	TNF α	Celltrion Pfizer Hospira (Pfizer)	Approved
infliximab biosimilar, Reliance Life Sciences	TNF α	Epirus Reliance	Approved
infliximab biosimilar, Bionovis/Instituto Vital		Bionovis	

infiximab biosimilar, Nichi-iko Pharmaceutical/Aprogen	TNF α	Nichi-iko Pharma Aprogen	Approved
infiximab biosimilar, Pfizer/Sandoz	TNF α	Hospira (Pfizer) Pfizer Sandoz (Novartis)	Approved
infiximab biosimilar, Biocad	TNF α	Biocad	Approved
infiximab biosimilar, Amgen	TNF α	Amgen	Approved
infiximab biosimilar, Mabtech/Sorrento Therapeutics	TNF α	Mabtech Limited Sorrento	Approved
infiximab biosimilar, 3SBio	TNF α	3SBio	Phase 3
iscalimab	CD40	Novartis Xoma	Phase 2
infiximab biosimilar, LG Chem	TNF α	LG Chem	Preclinical
JNJ-63823539	IL-17 TNF α	J&J Covagen	Phase 1
JNJ-67484703	Undisclosed	Janssen Biotech	Phase 1
keliximab	CD4	IDEC Pharmaceuticals (Biogen) SKB	Phase 3
KPL-404	CD40	Kiniksa	Phase 2
levilimab	IL-6	Biocad	Approved
MEDI-3617	Angiopoietin 2	Medimmune (AstraZeneca)	Phase 1
MDX-1342	CD19	Medarex (BMS)	Phase 1
NI-0101	TLR4	Edesa Light Chain	Phase 2
olokizumab	IL-6	UCB R-Pharm	Approved
otilimab	CSF2	MorphoSys GSK	Phase 3
ocaratumumab	CD20	AME Mentrik	Phase 2
ozoralizumab	TNF α Albumin	Ablynx (Sanofi) Eddingpharm Pfizer Taisho Pharma	Phase 2
plonmarlimab	GM-CSF	I-Mab Biopharma	Phase 3
placulumab	TNF α	Domantis Arana Therapeutics (Cephalon) Teva	Phase 2
peresolimab	PD-1	Lilly	Phase 2

